Clinical Trial

Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers

Study acronym: CARE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main objective is to evaluate the impact of a Regorafenib combined with metronomic chemotherapy (capecitabine and cyclophosphamide) and low-dose aspirin compared to standard Regorafenib treatment in patients with metastatic colorectal cancer by assessing progression-free survival.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-17; most recent amendment 2024-12-19.
Status change: Not Yet Recruiting → Recruiting 2024-12-19
Trial Details
NCT Number NCT06425133
Lead Sponsor Centre Hospitalier Universitaire de Besancon
Collaborators: Groupement Interrégional de Recherche Clinique et d'Innovation
Conditions Metastatic Colorectal Cancer
Enrollment 174 participants
Start Date 2024-07-19
Primary Completion 2027-09 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2024-12-24